We are live on ! Find out more
PHVS icon

Pharvaris

83 hedge funds and large institutions have $1.44B invested in Pharvaris in 2025 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

599% more capital inflows, than outflows

Capital inflows: $333M | Capital outflows: $47.7M

388% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 8

383% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 6

38% more funds holding

Funds holding: 60 → 83 (+23)

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

7.31% more ownership

Funds ownership: 82.65% → 89.96% (+7.3%)

Holders
83
Holders Change
+23
Holders Change %
+38.33%
% of All Funds
1.08%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
29
Increased
39
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PHVS Hedge Fund Activity: Q3 2025 in Review

83 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q3 2025, worth a combined $1.44B — up 82% from $793M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PHVS positions and 6 closed out — a net gain of 23 holders — while 39 added to existing stakes and 8 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $38.5M. The largest seller was VR Adviser, cutting an estimated $30.5M.

  • 83 institutional investors held Pharvaris (PHVS) as of Q3 2025, up from 60 in Q2 2025.
  • Funds reported $1.44B of Pharvaris stock for Q3 2025, up 82% quarter-over-quarter.
  • 29 funds opened new Pharvaris positions in Q3 2025 and 6 closed out, a net change of +23 holders.
  • The largest Pharvaris buyer in Q3 2025 was Wellington Management Group, an estimated $38.5M added.
  • The largest Pharvaris seller in Q3 2025 was VR Adviser, an estimated $30.5M sold.

Based on aggregated 13F filings for Q3 2025.